Copy of A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple- Dose BIVV009 in Participants With Chronic Immune Thrombocytopenia (ITP)

The purpose of this study is to explore the safety, preliminary clinical benefit, and activity of BIVV009 in patients with chronic immune thrombocytopenia. BIVV009 has been designed to block the pathway that triggers the immune system to remove damaged cells. It is believed that this approach may limit the number of cells immune system removes and allow the extra cells to help promote platelet production.

USA, United Kingdom, Germany


back to top

BBB Cleveland logo GuideStar Seal NORD Member Badge 2018THSNA logo